Nucleoside-based Production Service
Characterization of Nucleosides
A nucleoside is an organic molecule that is made up of a nitrogenous base and a sugar molecule. The sugar within a nucleoside can be either ribose or deoxyribose, which is attached by glycoside bonds to the nitrogen-containing base. It can be thought of as a nucleotide that has no phosphate group. Nucleosides are important parts of DNA and RNA and play a crucial role in the storage and transmission of genetic information. Nitrogenous bases in nucleosides can be one of a few types, including adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U). A particular composition of nitrogen-containing bases and sugar molecules determines the type of nucleoside. Nucleosides play an essential role in cellular functions. They are engaged in DNA copying, transcription, and translation, which are vital for the storing and expression of genetic information. Nucleosides also have other functions in cell signaling and metabolism.
Key Technologies
We employ advanced chemical synthesis and purification techniques to produce diverse sugar-nucleosides. Its core innovation is a novel method utilizing 2'-deoxyribonucleoside 5'-phosphites as monomer units, fundamentally differing from traditional phosphoramidite/H-phosphonate approaches.
A key advancement is the use of base-unprotected 2'-deoxyribonucleoside 5'-phosphites. This eliminates complex nucleobase protection/deprotection steps, streamlining synthesis while boosting efficiency and reducing side reactions. These monomers are synthesized in a simple, one-step reaction from parent nucleosides.
The synthetic cycle involves robust chain elongation: the monomer's 3'-OH group condenses with the growing oligomer's 5'-terminal H-phosphonate monoester. Critical to this cycle is the rapid, quantitative removal of phosphite protecting groups to regenerate the H-phosphonate monoester for subsequent condensations.
This methodology enables the synthesis of diverse sugar-nucleosides and analogs, providing a versatile platform for clients.
Nucleoside-based Production Service at CD BioGlyco
There are many different types of nucleosides, and CD BioGlyco offers nucleosides production services that include, but are not limited to:

Nitrogenous bases are the essential components of nucleosides. At CD BioGlyco, we offer nucleoside production services on adenine, cytosine, guanine, uracil, and thymine. We have both biological and chemical routes to choose from in the production of nitrogenous bases, and we offer custom production solutions to each of our clients.
![]()
Ribonucleosides play an important role in living organisms and are part of RNA. CD BioGlyco offers ribonucleoside-based production of adenosine, cytosine, guanosine, uridine, and 5-methyluridine. We have multiple routes for each riboside and are constantly optimizing our production solutions to ensure the most efficient production for our clients.

Another part of nucleosides is deoxyribonucleoside, which is also a component of DNA. At CD BioGlyco, we offer services in the production of deoxyadenosine, deoxyguanosine, thymidine, uridine, and deoxycytidine. During the production process, we provide our clients with the most suitable production solution.
Nucleoside-based derivatives of nucleosides are also important for the human body. For this reason, we also offer nucleoside-based derivative production services.
- Deoxyadenosine Derivative Production
- Deoxycytidine Derivative Production
- Deoxyguanosine Derivative Production
- Deoxythymidine Derivative Production
- Deoxyuridine Derivative Production
- Dideoxynucleotide Derivative Production
- Adenosine Derivative Production
- Adenine Derivative Production
- Cytosine Derivative Production
Workflow
Our sugar-nucleoside production service is designed as a collaborative and efficient process to ensure the highest quality results for your project.
- Project Consultation and Design
The process starts with a detailed consultation with our expert scientific team. We work with you to define your specific needs, including the exact structure of the sugar-nucleoside, desired quantity, and purity requirements. We then design a custom synthesis plan to meet these specifications.
- Monomer Unit Synthesis
We begin by preparing the necessary monomer units, employing a simple one-step reaction from base-unprotected 2'-deoxyribonucleosides. For nucleosides that are less soluble, like 2'-deoxycytidine and 2'-deoxyguanosine, we use co-solvents such as N-methylpyrrolidone (NMP) with pyridine to significantly improve solubility and enhance reaction selectivity.
- Chain Elongation and Synthesis
This stage involves the sequential addition of monomer units to build the target sugar-nucleoside or oligonucleotide. Our chain elongation cycle includes three key steps: deprotection, condensation, and capping. The use of H-phosphonate intermediates enables the synthesis of a wide variety of DNA analogs that are not accessible via other methods.
- Purification and Quality Assurance
After synthesis, the crude product undergoes a rigorous purification process. We leverage advanced chromatographic techniques, and in some cases, the monomer units can be easily purified by crystallization. Each batch is then subjected to a comprehensive quality control assessment, including NMR, HPLC, and mass spectrometry, to confirm its identity, structure, and purity.
- Final Product Delivery
The high-purity, quality-controlled sugar-nucleoside is delivered with a detailed certificate of analysis (CoA), providing you with complete confidence in the product's quality and specifications.
Publication Data
DOI.: 10.3390/molecules27113499
Journal: Molecules
IF: 4.6
Published: 2020
Results: This study synthesized seven modified sugar and nucleoside analogs (compounds 2-8) from α-D-glucose through a 21-step pathway. The compounds were evaluated for analgesic activity in mice using acetic acid-induced writhing assays and for cytotoxicity against HeLa cancer cells via trypan blue exclusion and CCK-8 assays. Key findings include:
- Compounds 2, 7, and 8 significantly reduced writhing by 56%, 62%, and 63%, respectively, indicating potent peripheral analgesia.
- Compound 6 exhibited notable cytotoxicity with an IC50 of 54 µg/mL against HeLa cells.Molecular docking revealed that analgesic compounds 2, 7, and 8 bind strongly to cyclooxygenase-1/2 (COX-1/2) and adenosine kinase, suggesting dual inhibition pathways. Cytotoxic compound 6 showed high affinity for cancer targets like cytidine deaminase, tyrosine-protein kinase Src, and thymidine kinase 1. This work presents the first report of compound 8's synthesis/analgesia and compound 6's anticancer potential, highlighting their therapeutic promise.
Application
- Nucleic Acid-Based Therapeutics
Our nucleosides are used in the synthesis of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers for targeted gene regulation and therapeutic intervention.
- Antiviral and Anticancer Drug Discovery
Many antiviral and anticancer drugs are nucleoside analogs, and our service is critical for the research of these therapeutic agents.
- Genetic and Epigenetic Research
Modified nucleosides are vital tools for studying DNA and RNA structure, function, and epigenetic modifications, offering insights into gene expression and disease mechanisms.
Advantage
- Our method uses base-unprotected nucleoside phosphites as monomer units, which simplifies the overall synthetic process. This innovative approach eliminates the need for complex protection and deprotection steps, making the synthesis faster and more efficient.
- We have optimized our one-step reaction to synthesize monomer units in good yields, and these compounds can be readily purified by crystallization.
- The H-phosphonate intermediates generated by our method are highly versatile and serve as excellent precursors for synthesizing a wide range of DNA analogs that are challenging to obtain through conventional phosphoramidite chemistry.
Frequently Asked Questions
Associated Services
Our nucleoside production services provide high-purity molecular building blocks (adenine, cytosine, guanine, uracil, thymine) essential for synthesizing oligonucleotide therapeutics. To transform these nucleosides into functionally advanced constructs, we offer precision Oligonucleotide Modification Services that enhance stability, targeting, and therapeutic efficacy:
- Oligonucleotide-based Affinity-plus Base Modification Service
- Oligonucleotide-based Inosine Modification Service
- Oligonucleotide-based 2'-O-methoxy-ethyl Bases (2'-MOE) Modification Service
- Oligonucleotide-based 2'-O-Methyl RNA Bases Modification Service
- Oligonucleotide-based Fluoro Bases Modification Service
CD BioGlyco is a company with extensive experience in the manufacturing of nucleosides and their derivatives. Our versatile analytical platform and specialized researchers provide custom production services. If you are interested in our services, please do not hesitate to contact us.
Reference
- Hussain, F.; et al. Synthesis of sugar and nucleoside analogs and evaluation of their anticancer and analgesic potentials. Molecules. 2020, 27(11): 3499. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




